Infantile Fibrosarcoma and Other Solid Tumors Respond Well to Precision Medicine
There’s new evidence that Larotrectinib (Vitrakvi), by Loxo Oncology and Bayer, is highly effective in children with newly diagnosed infantile fibrosarcoma (IFS) or other solid tumors.
Comentários